Cognition Therapeutics Reveals Encouraging Results from Phase 2 COG1201 SHIMMER Study

Cognition Therapeutics, Inc. recently disclosed significant findings from its Phase 2 COG1201 SHIMMER study through a slide presentation. The company has attached the presentation as Exhibit 99.1 to its latest Current Report on Form 8-K.

The SHIMMER study was designed to evaluate the multifactorial burden associated with Dementia with Lewy Bodies (DLB). This study was conducted in collaboration with LBDA Centers of Excellence, academic centers, and industry partners, partially funded by a $30 million National Institute on Aging (NIA) grant.

Key findings from the study demonstrated promising results with Cognition Therapeutics’ CT1812 treatment. Participants receiving CT1812 showed remarkable improvements across various domains compared to those on a placebo, with up to 91% slowing of cognitive decline, 52% preservation in activities of daily living measures, and 62% preservation in motor function.

Additionally, the safety profile of CT1812 was favorable, with adverse events similar to those observed in prior trials. Most adverse events were mild to moderate, and there were no deaths related to the study drug.

The company expressed its intention to present the study’s data at the ILBDC in January 2025, convene advisors for protocol input, engage with regulatory experts, conduct commercial research, and prepare for end-of-Phase 2 meetings.

Cognition Therapeutics is optimistic about the potential of CT1812 as a treatment for Dementia with Lewy Bodies, supported by consistent signals of efficacy and a safe and tolerable dose range observed in the SHIMMER study.

The company expressed gratitude to all participants, care partners, University of Miami, NIH, NIA, site investigators, collaborators, and Cognition colleagues involved in the successful execution of the COG1201 SHIMMER Trial.

The study’s outcomes have met and exceeded objectives and expectations, aligning with Cognition Therapeutics’ mission to address the challenges associated with neurological diseases like DLB.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Cognition Therapeutics’s 8K filing here.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.